Exciting news from the European healthcare landscape! The European Medicines Agency has just approved the world’s first mRNA-based vaccine specifically designed to prevent chronic Lyme disease. This innovative solution leverages advanced mRNA technology—previously celebrated for its role in COVID-19 vaccines—to address a growing public health concern across Europe and beyond. For healthcare professionals, this marks a significant milestone in infectious disease prevention and offers new hope for at-risk populations. Explore what this means for your practice and the evolving role of mRNA therapeutics in tackling persistent diseases.